<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1902">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075435</url>
  </required_header>
  <id_info>
    <org_study_id>2019P002466</org_study_id>
    <nct_id>NCT04075435</nct_id>
  </id_info>
  <brief_title>Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer's Dementia</brief_title>
  <acronym>CBD</acronym>
  <official_title>Open-Label Trial of a Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer's Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spier Family Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, eight week, clinical trial of a proprietary high CBD/low THC&#xD;
      sublingual solution for the treatment of clinically significant anxiety and agitation in mild&#xD;
      to moderate Alzheimer's Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">January 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 11, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open label trial; all participants will receive active drug.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total of clinician impression column on anxiety domain of the NPI-C</measure>
    <time_frame>Continuous, weeks 0-8</time_frame>
    <description>Measure of Anxiety Domain on the Neuropsychiatric Inventory-Clinician scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total score on the Generalized Anxiety Disorder 7 scale</measure>
    <time_frame>Continuous, week 0-8</time_frame>
    <description>Secondary Outcome Measure of anxiety reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events</measure>
    <time_frame>Continuous, weeks 0-8</time_frame>
    <description>Secondary Outcome Measure of safety defined by absence of serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Week 8 MMSE total score compared to baseline MMSE total score</measure>
    <time_frame>longitudinal: screening/baseline and week8</time_frame>
    <description>Secondary Outcome Measure of safety as defined by lack of treatment emergent cognitive impairment as measured by the Mini Mental Status Exam (MMSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on the confusion assessment method</measure>
    <time_frame>Continuous screening weeks 0-8, dichotomous</time_frame>
    <description>Secondary Outcome Measure of safety defined as absence of treatment emergent delirium as measured by the Confusion Assessment Method (CAM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of side effects reported</measure>
    <time_frame>Continuous, weeks 0-8</time_frame>
    <description>Secondary Outcome Measure of safety defined as a low number of emergent somatic side effects as measured by the Medication Side Effects Questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total clinical impression column score on neuropsychiatric inventory agitation and aggression domains (NPI-C)</measure>
    <time_frame>Continuous, weeks 0-8</time_frame>
    <description>Exploratory measure to see reduction in agitation and aggression symptoms</description>
  </other_outcome>
  <other_outcome>
    <measure>Total score of Cohen-Mansfield Inventory (CMAI)</measure>
    <time_frame>Continuous, weeks 0-8</time_frame>
    <description>Exploratory measure to see reduction in agitation symptoms</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Score of Zarit Caregiver Burden Interview</measure>
    <time_frame>Continuous, weeks 0-8</time_frame>
    <description>Exploratory downstream reduction in caregiver burden</description>
  </other_outcome>
  <other_outcome>
    <measure>Stability of anxiety and agitation reduction using anxiety domain of NPI-C and GAD-7</measure>
    <time_frame>Months 3, 6, 9, and 12 of the optional follow-up phase</time_frame>
    <description>Exploratory investigation into the stability of anxiety reduction using the anxiety domain score on the NPI-C and the GAD-7 during the optional follow-up phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Stability of caregiver burden reduction</measure>
    <time_frame>Months 3, 6, 9, and 12 of the optional follow-up phase</time_frame>
    <description>Exploratory investigation into reduction of caregiver burden using the Zarit Caregiver Burden Interview during the optional follow-up phase</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Anxiety</condition>
  <condition>Agitation,Psychomotor</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm will include all subjects, individuals will administer a high CBD, low THC full spectrum sublingual solution twice daily on a variable dosing schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high CBD/low THC sublingual solution</intervention_name>
    <description>Hemp derived solution to be administered sublingually twice daily.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of probable Alzheimer's Dementia via criteria from McKhann et al.&#xD;
&#xD;
          2. MMSE score of 15-24 (inclusive)&#xD;
&#xD;
          3. Clinically significant degree of anxiety, as defined by a Clinical Impression total&#xD;
             column score of â‰¥4 on the Anxiety domain of the NPI-C&#xD;
&#xD;
          4. A health care proxy available to sign consent on behalf of the participant (if&#xD;
             applicable)&#xD;
&#xD;
          5. A caregiver who spends at least 10 hours per week with the subject who is able to&#xD;
             attend all study visits&#xD;
&#xD;
          6. Participants and their study partner must be fluent in English&#xD;
&#xD;
          7. Must be 60-90 years old (inclusive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious or unstable medical illness, including cardiovascular, hepatic, renal,&#xD;
             respiratory, endocrine, neurologic or hematologic disease, which might confound&#xD;
             assessment of safety outcomes.&#xD;
&#xD;
          2. Seizure disorder&#xD;
&#xD;
          3. Lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, as&#xD;
             determined by the MINI&#xD;
&#xD;
          4. Current episode of major depression, as determined by the MINI&#xD;
&#xD;
          5. Active substance abuse or dependence within the past 6 months, as determined by the&#xD;
             MINI&#xD;
&#xD;
          6. Delirium (as measured by the CAM)&#xD;
&#xD;
          7. Current inpatient hospitalization&#xD;
&#xD;
          8. Current regular use of cannabinoid products (&gt;1 use per month)&#xD;
&#xD;
          9. Positive urine screen for THC at the screening or baseline visit&#xD;
&#xD;
         10. Allergy to coconut&#xD;
&#xD;
         11. Participants taking strong inhibitors or inducers of CYP3A4 (e.g. fluconazole,&#xD;
             fluoxetine, fluvoxamine, ticlopidine, St. John's Wort, etc.), CYP2C19 (ketoconazole,&#xD;
             erythromycin, etc.), or anti-epileptic drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brent P Forester, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Staci Gruber, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kaitlin McManus, BA</last_name>
    <phone>617-855-3192</phone>
    <email>kmcmanus@mclean.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosemary Smith, BS</last_name>
    <phone>617-855-2908</phone>
    <email>rsmith@mclean.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent Forester, MD</last_name>
      <phone>617-855-3622</phone>
      <email>bforester@mclean.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Brent P Forester, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Staci Gruber, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>April 4, 2022</last_update_submitted>
  <last_update_submitted_qc>April 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Staci Gruber, Ph.D.</investigator_full_name>
    <investigator_title>Directory, Cognitive and Clinical Neuroimaging Core; Director, Marijuana Investigations for Neuroscientific Discovery (MIND)</investigator_title>
  </responsible_party>
  <keyword>cannabidiol</keyword>
  <keyword>older adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Behavioral Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

